iFrame is not supported! Endocrine Therapy: SABCS 2022 Halle Moore POSITIVE Trial Breast Cancer How does endocrine therapy (aromatase inhibitor) effect women with endocrine responsIVE breast cancer? The POSITIVE study which was presented at this year’s San Antonio Breast Cancer Symposium (SABCS) was a prospective clinical trial designed to evaluate the safety of and pregnancy outcomes with interrupting endocrine therapy for early stage hormone receptor positive breast cancer in order to attempt pregnancy. Young women with early stage hormone receptor positive breast cancer were eligible for the trial if they desired pregnancy and had completed 18 to 36…
Author: Editor
Endocrine Therapy: SABCS 2022 Halle Moore POSITIVE Trial Breast Cancer How does endocrine therapy (aromatase inhibitor) effect women with endocrine responsIVE breast cancer? The POSITIVE study which was presented at this year’s San Antonio Breast Cancer Symposium (SABCS) was a prospective clinical trial designed to evaluate the safety of and pregnancy outcomes with interrupting endocrine therapy for early stage hormone receptor positive breast cancer in order to attempt pregnancy. Young women with early stage hormone receptor positive breast cancer were eligible for the trial if they desired pregnancy and had completed 18 to 36 months of adjuvant endocrine therapy.…
iFrame is not supported! IPSS: ASH 2022 Roger Lyons Treatment Pattern and Overall Survival MDS By Roger M. Lyons, MD, FACP What is the IPSS and the IPSS-R scoring systems and how will this help patients with MDS? This is a study that took place over 10 years looking at the US Oncology iKnowMed medical record system to define the course of patients with a myelodysplasia. There were 1400 physicians involved in the trial. So it’s a huge database. Of course, this was not a prospective study, so some of the data is not absolutely in a form that…
iFrame is not supported! IPSS: ASH 2022 Roger Lyons Treatment Pattern and Overall Survival MDS By Roger M. Lyons, MD, FACP What is the IPSS and the IPSS-R scoring systems and how will this help patients with MDS? This is a study that took place over 10 years looking at the US Oncology iKnowMed medical record system to define the course of patients with a myelodysplasia. There were 1400 physicians involved in the trial. So it’s a huge database. Of course, this was not a prospective study, so some of the data is not absolutely in a form that…
IPSS: ASH 2022 Roger Lyons Treatment Pattern and Overall Survival MDS By Roger M. Lyons, MD, FACP What is the IPSS and the IPSS-R scoring systems and how will this help patients with MDS? This is a study that took place over 10 years looking at the US Oncology iKnowMed medical record system to define the course of patients with a myelodysplasia. There were 1400 physicians involved in the trial. So it’s a huge database. Of course, this was not a prospective study, so some of the data is not absolutely in a form that can you be used…
Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the diagnosis and treatment of pregnant women with a prior diagnosis of TMAs, or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy, specifically TTP and complement mediated HRES, are rare disease in these patients. Eventually, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for that? And the reality is that compliment plays an…
iFrame is not supported! Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the diagnosis and treatment of pregnant women with a prior diagnosis of TMAs, or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy, specifically TTP and complement mediated HRES, are rare disease in these patients. Eventually, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for that? And the reality is…
Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the diagnosis and treatment of pregnant women with a prior diagnosis of TMAs, or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy, specifically TTP and complement mediated HRES, are rare disease in these patients. Eventually, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for that? And the reality is that compliment plays an…
FGFR2: Breast Cancer Suneel Kamath SABCS 2022 ReFocus Trial How can FGFR2 inhibitors like RLY-4008 help with patients suffering with cholangiocarcinoma and what makes it a clinical significance? The ReFocus study is a trial, it’s a phase 1/2B study including all solid tumors, mainly focused on cholangiocarcinoma, and some other separate subsets including breast cancer, some of the GYN malignancies as well. Looking at a novel FGFR2 inhibitor RLY-4008. So there are several existing FGFR2 (tyrosine kinase) inhibitors in cholangiocarcinoma and bladder cancer. And all of them look to be quite effective and really great treatment options, but many…
iFrame is not supported! FGFR2: Breast Cancer Suneel Kamath SABCS 2022 ReFocus Trial How can FGFR2 inhibitors like RLY-4008 help with patients suffering with cholangiocarcinoma and what makes it a clinical significance? The ReFocus study is a trial, it’s a phase 1/2B study including all solid tumors, mainly focused on cholangiocarcinoma, and some other separate subsets including breast cancer, some of the GYN malignancies as well. Looking at a novel FGFR2 inhibitor RLY-4008. So there are several existing FGFR2 (tyrosine kinase) inhibitors in cholangiocarcinoma and bladder cancer. And all of them look to be quite effective and really great…
FGFR2: Breast Cancer Suneel Kamath SABCS 2022 ReFocus Trial How can FGFR2 inhibitors like RLY-4008 help with patients suffering with cholangiocarcinoma and what makes it a clinical significance? The ReFocus study is a trial, it’s a phase 1/2B study including all solid tumors, mainly focused on cholangiocarcinoma, and some other separate subsets including breast cancer, some of the GYN malignancies as well. Looking at a novel FGFR2 inhibitor RLY-4008. So there are several existing FGFR2 (tyrosine kinase) inhibitors in cholangiocarcinoma and bladder cancer. And all of them look to be quite effective and really great treatment options, but many…
Bisphosphonates: Breast Cancer Julia Foldi SABCS 2022 Cohort Study How can BMAs (zoledronic acid) help oncology patients with early-stage breast cancer in the United States and not in other countries? I’m talking about our study looking at patterns of adjuvant bone modifying use in patients with early stage breast cancers. Bone modifying agents, particularly bisphosphonates, not only help preserve bone density (or bone material loss) in postmenopausal women receiving endocrine therapy for treatment of breast cancer, but we also know that they reduce the risk of breast cancer recurrence as well as reduce the risk of breast cancer specific…
iFrame is not supported! Bisphosphonates: Breast Cancer Julia Foldi SABCS 2022 Cohort Study How can BMAs (zoledronic acid) help oncology patients with early-stage breast cancer in the United States and not in other countries? I’m talking about our study looking at patterns of adjuvant bone modifying use in patients with early stage breast cancers. Bone modifying agents, particularly bisphosphonates, not only help preserve bone density (or bone material loss) in postmenopausal women receiving endocrine therapy for treatment of breast cancer, but we also know that they reduce the risk of breast cancer recurrence as well as reduce the risk…
Bisphosphonates: Breast Cancer Julia Foldi SABCS 2022 Cohort Study How can BMAs (zoledronic acid) help oncology patients with early-stage breast cancer in the United States and not in other countries? I’m talking about our study looking at patterns of adjuvant bone modifying use in patients with early stage breast cancers. Bone modifying agents, particularly bisphosphonates, not only help preserve bone density (or bone material loss) in postmenopausal women receiving endocrine therapy for treatment of breast cancer, but we also know that they reduce the risk of breast cancer recurrence as well as reduce the risk of breast cancer specific…
Polatuzumab-Rituximab: RR DLBCL Ariel Perez ASH 2022 Second-Line Therapy By Ariel Perez Perez, MD What did the combination of Polatuzumab-Rituximab either with our without Bendamustine show in this clinical trial? So our study is a retrospective study of patients treated with Polatuzumab Vedotin which is a CD79 antibody drug conjugate in combination with Rituximab plus the addition of Bendamustine in the patient population with relapsed refractory large b-cell lymphoma (RR DLBCL). Our aim was to analyze the institutional outcomes of patients treated with this regimen. And as well, we wanted to look at the pattern of failure to front-line therapy,…
iFrame is not supported! Polatuzumab-Rituximab: RR DLBCL Ariel Perez ASH 2022 Second-Line Therapy By Ariel Perez Perez, MD What did the combination of Polatuzumab-Rituximab either with our without Bendamustine show in this clinical trial? So our study is a retrospective study of patients treated with Polatuzumab Vedotin which is a CD79 antibody drug conjugate in combination with Rituximab plus the addition of Bendamustine in the patient population with relapsed refractory large b-cell lymphoma (RR DLBCL). Our aim was to analyze the institutional outcomes of patients treated with this regimen. And as well, we wanted to look at the pattern of…
Polatuzumab-Rituximab: RR DLBCL Ariel Perez ASH 2022 Second-Line Therapy By Ariel Perez Perez, MD What did the combination of Polatuzumab-Rituximab either with our without Bendamustine show in this clinical trial? So our study is a retrospective study of patients treated with Polatuzumab Vedotin which is a CD79 antibody drug conjugate in combination with Rituximab plus the addition of Bendamustine in the patient population with relapsed refractory large b-cell lymphoma (RR DLBCL). Our aim was to analyze the institutional outcomes of patients treated with this regimen. And as well, we wanted to look at the pattern of failure to front-line therapy,…
Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the clinical diagnosis and treatment of pregnant women with a prior diagnosis of TMAs or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy (TMA), specifically TTP and complement-mediated HRES are rare diseases, patients eventually may become, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for. And the reality is that complement plays…
MammaPrint: Breast Cancer Dr. Nasrazadani SABCS 2022 70-gene 10 Year Follow Up What has this 10 year follow up on this clinical data shown in patients with early-stage breast cancer? So this is in a real world retrospective study utilizing the 70-gene MammaPrint assay in a cohort of patients at UPMC of patients that were diagnosed with early stage breast cancer between 2005 to 2008, specifically looking at the ability to prognosticate, with regard to distant metastasis free interval, in patients that have an either low risk or high risk MammaPrint (test or genetic testing) index with the low…
iFrame is not supported! Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the clinical diagnosis and treatment of pregnant women with a prior diagnosis of TMAs or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy (TMA), specifically TTP and complement-mediated HRES are rare diseases, patients eventually may become, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for. And the reality…
Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the clinical diagnosis and treatment of pregnant women with a prior diagnosis of TMAs or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy (TMA), specifically TTP and complement-mediated HRES are rare diseases, patients eventually may become, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for. And the reality is that complement plays…
iFrame is not supported! MammaPrint: Breast Cancer Dr. Nasrazadani SABCS 2022 70-gene 10 Year Follow Up What has this 10 year follow up on this clinical data shown in patients with early-stage breast cancer? So this is in a real world retrospective study utilizing the 70-gene MammaPrint assay in a cohort of patients at UPMC of patients that were diagnosed with early stage breast cancer between 2005 to 2008, specifically looking at the ability to prognosticate, with regard to distant metastasis free interval, in patients that have an either low risk or high risk MammaPrint (test or genetic testing)…
MammaPrint: Breast Cancer Dr. Nasrazadani SABCS 2022 70-gene 10 Year Follow Up What has this 10 year follow up on this clinical data shown in patients with early-stage breast cancer? So this is in a real world retrospective study utilizing the 70-gene MammaPrint assay in a cohort of patients at UPMC of patients that were diagnosed with early stage breast cancer between 2005 to 2008, specifically looking at the ability to prognosticate, with regard to distant metastasis free interval, in patients that have an either low risk or high risk MammaPrint (test or genetic testing) index with the low…
iFrame is not supported! Biomarkers: Breast Cancer – Daniel Rotroff SABCS 2022 GENIE Trial What will help identify (biomarkers) genetics and inflammatory markers that predict chemotherapy-induced peripheral neuropathy? So the GENIE Study aims to develop biomarkers for peripheral neuropathy in patients treated with taxane chemotherapy for breast cancer patients. Peripheral neuropathy occurs in about 70% of patients with breast cancer. They’re treated with taxanes. Most of those patients will have relatively mild symptoms that resolve shortly after their infusion. But in a subset of patients, those symptoms can be pretty severe. And in some patients, that can also persist…
Biomarkers: Breast Cancer – Daniel Rotroff SABCS 2022 GENIE Trial What will help identify (biomarkers) genetics and inflammatory markers that predict chemotherapy-induced peripheral neuropathy? So the GENIE Study aims to develop biomarkers for peripheral neuropathy in patients treated with taxane chemotherapy for breast cancer patients. Peripheral neuropathy occurs in about 70% of patients with breast cancer. They’re treated with taxanes. Most of those patients will have relatively mild symptoms that resolve shortly after their infusion. But in a subset of patients, those symptoms can be pretty severe. And in some patients, that can also persist for months or even…
Test 2
Test
iFrame is not supported! Nemtabrutinib: Jennifer Woyach, MD ASH 2022 – BELLWAVE-001 Study By Jennifer Woyach, MD What did the BELLWAVE-01 study on Nemtabrutinib reveal in patients with relapsed refractory CLL and SLL? So we presented follow up from the phase 1/2 BELLWAVE-001 study of nemtabrutinib in patients with relapsed refractory CLL and SLL. So nemtabrutinib is a non-covalent BTK bruton tyrosine kinase inhibitors (BTKis). It was designed to be able to bind BTK outside of the C481 site, which is where the covalent BTK inhibitors bind. So the idea is that this will be an effective agent, even if…
Nemtabrutinib: Jennifer Woyach, MD ASH 2022 – BELLWAVE-001 Study By Jennifer Woyach, MD What did the BELLWAVE-01 study on Nemtabrutinib reveal in patients with relapsed refractory CLL and SLL? So we presented follow up from the phase 1/2 BELLWAVE-001 study of nemtabrutinib in patients with relapsed refractory CLL and SLL. So nemtabrutinib is a non-covalent BTK bruton tyrosine kinase inhibitors (BTKis). It was designed to be able to bind BTK outside of the C481 site, which is where the covalent BTK inhibitors bind. So the idea is that this will be an effective agent, even if patients develop resistance mutations…
iFrame is not supported! Notable Labs: Thomas Bock ASH 2022 The Future of AML Treatment By Thomas Bock, MD, MBA Where is the blood cancer treatment for the patient population with AML? There is such a momentum of new data for acute myeloid leukemia (AML blood cancer) here at this congress, and compared with the early days of chronic myelogenous leukemia and multiple myeloma, where such great medical progress was made, within a few years, we (Notable Labs) had the opportunity to present data just here in New Orleans on juvenile myelomonocytic leukemia. It’s a very rare disease. It is…
Notable Labs: Thomas Bock ASH 2022 The Future of AML Treatment By Thomas Bock, MD, MBA Where is the blood cancer treatment for the patient population with AML? There is such a momentum of new data for acute myeloid leukemia (AML blood cancer) here at this congress, and compared with the early days of chronic myelogenous leukemia and multiple myeloma, where such great medical progress was made, within a few years, we (Notable Labs) had the opportunity to present data just here in New Orleans on juvenile myelomonocytic leukemia. It’s a very rare disease. It is for collaboration with UCSF’s…
iFrame is not supported! Everolimus: Julie Gralow SABCS 2022 SWOG S1207 in HER2- Breast Cancer What is Everolimus and how can it help patients with HR+ HER2-negative breast cancer? The SWOG S1207 was a trial in the adjuvant breast cancer setting for patients that have hormone receptor positive and HER two negative breast cancer that certain criteria for being at high risk (increased risk) for a distant recurrence. So all patients in this study got endocrine therapy, it could be endocrine therapy of choice, so ovarian function suppression, Tamoxifen, or an aromatase inhibitor and then they were randomized…
Everolimus: Julie Gralow SABCS 2022 SWOG S1207 in HER2- Breast Cancer What is Everolimus and how can it help patients with HR+ HER2-negative breast cancer? The SWOG S1207 was a trial in the adjuvant breast cancer setting for patients that have hormone receptor positive and HER two negative breast cancer that certain criteria for being at high risk (increased risk) for a distant recurrence. So all patients in this study got endocrine therapy, it could be endocrine therapy of choice, so ovarian function suppression, Tamoxifen, or an aromatase inhibitor and then they were randomized to either placebo or…
iFrame is not supported! VERIFY Trial PV: ASH 2022 Phase 3 Study on PTG-300 Srdan Verstovsek By Srdan Verstovsek, MD, PhD How will the VERIFY clinical trial of PTG-300 help patients with polycythemia vera? I’m going to talk about this poster number 1709, which is a presentation of the VERIFY study, a phase 3 study of the Hepcidin Mimetic Rusfertide, also known as PTG-300. In patients with polycythemia vera, this is the study that is underway based on the outcome of the phase 2 open label study with this particular medication. Now, Rusfertide is hepcidin mimetic. What that means…
VERIFY Trial PV: ASH 2022 Phase 3 Study on PTG-300 Srdan Verstovsek By Srdan Verstovsek, MD, PhD How will the VERIFY clinical trial of PTG-300 help patients with polycythemia vera? I’m going to talk about this poster number 1709, which is a presentation of the VERIFY study, a phase 3 study of the Hepcidin Mimetic Rusfertide, also known as PTG-300. In patients with polycythemia vera, this is the study that is underway based on the outcome of the phase 2 open label study with this particular medication. Now, Rusfertide is hepcidin mimetic. What that means is that it is…
RxPONDER trial (SWOG S1007) at SABCS 2022 presented by Yara Abdou, MD from the University of North CarolinaGS1-01 Race and clinical outcomes in the RxPONDER trial (SWOG S1007)Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU,
iFrame is not supported! SV-BR-1-GM: Turning Cells into Antigen-presenting Cells Dr. Williams SABCS 2022 How does SV-BR-1-GM help turn cells into antigen-presenting cells? Now our next presentation was looking at our pipeline development, capitalizing on the observations we’ve. With the Bria-IMT therapy we’ve decided to take our cell line and some other cancer cell lines and to modify them so that they express different HLA types. I mentioned in our monotherapy and in our combination therapy experience with Bria-IMT, that there appears to be a clinical benefit associated with having an HLA match. With the Bria-IMT cell line.…
SV-BR-1-GM: Turning Cells into Antigen-presenting Cells Dr. Williams SABCS 2022 How does SV-BR-1-GM help turn cells into antigen-presenting cells? Now our next presentation was looking at our pipeline development, capitalizing on the observations we’ve. With the Bria-IMT therapy we’ve decided to take our cell line and some other cancer cell lines and to modify them so that they express different HLA types. I mentioned in our monotherapy and in our combination therapy experience with Bria-IMT, that there appears to be a clinical benefit associated with having an HLA match. With the Bria-IMT cell line. So by adding or…
iFrame is not supported! Idecabtagene: ASH 2022 Multiple Myeloma Madhav Dhodapkar KarMMa-2 By Madhav Dhodapkar, MBBS What is Idecabtagene, and how can it help patients with multiple myeloma? The data that I’m gonna present at the ASH meeting this year is relates to a specific cohort of the KarMMa trial called KarMMa-2 Cohort 2c. And this is a cohort that involves patients who had achieved suboptimal response following autologous stem cell transplantations. These are myeloma patients that have gone through initial induction therapy and stem cell transplantation, but have not achieved a complete remission. And these people were treated with…
Idecabtagene: ASH 2022 Multiple Myeloma Madhav Dhodapkar KarMMa-2 By Madhav Dhodapkar, MBBS What is Idecabtagene, and how can it help patients with multiple myeloma? The data that I’m gonna present at the ASH meeting this year is relates to a specific cohort of the KarMMa trial called KarMMa-2 Cohort 2c. And this is a cohort that involves patients who had achieved suboptimal response following autologous stem cell transplantations. These are myeloma patients that have gone through initial induction therapy and stem cell transplantation, but have not achieved a complete remission. And these people were treated with a single dose. Of…
iFrame is not supported! Isatuximab: ASH 2022 Multiple Myeloma Paul Richardson ICARIA By Paul Richardson, MD What can Pomalidomide/Dexamethasone do for Relapsed/Refractory Multiple Myeloma Patients? ICARIA-MM study was a randomized phase 3 international trial in which we compared Pomalidomide/Dexamethasone to the combination of Isatuximab, Pomalidomide, Dexamethasone and we showed the significant PFS (progression-free survival) benefit. And very importantly at this meeting we presented a survival update, which showed significant survival gains. Now, one of the most important things about the drug is that Isatuximab is obviously similar to Daratumumab and when you have patients in whom Daratumumab was used after…
Isatuximab: ASH 2022 Multiple Myeloma Paul Richardson ICARIA By Paul Richardson, MD What can Pomalidomide/Dexamethasone do for Relapsed/Refractory Multiple Myeloma Patients? ICARIA-MM study was a randomized phase 3 international trial in which we compared Pomalidomide/Dexamethasone to the combination of Isatuximab, Pomalidomide, Dexamethasone and we showed the significant PFS (progression-free survival) benefit. And very importantly at this meeting we presented a survival update, which showed significant survival gains. Now, one of the most important things about the drug is that Isatuximab is obviously similar to Daratumumab and when you have patients in whom Daratumumab was used after they had progressed on…
iFrame is not supported! Omentum Based Reconstruction: For Pts with BMI < 25 kg/m Dr. Wapnir SABCS 2022 Will this data analysis or data collection help with patients that receive omentum based reconstruction? One of the benefits that we’re noticing about this procedure is that patients really do not suffer any of the classical morbidities associated with donor sites. Prolonged drainage, large scars, and other deformities seem to have shortened the length of stay in the hospital, and again, there have been no donor sites or symptoms of donor site morbidities for many years. Dr. Nguyen and I recognized…
iFrame is not supported! Tumor-Associated Macrophages: BDC-3042 Animal Model Dr. Kenkel SITC 2022 What are tumor-associated macrophages? Our antibody that we refer to as BDC-3042 targets a molecule known as Dectin-2. This is a potent immune-activating receptor expressed by tumor-associated macrophages, or TAMs, across various types of human solid tumors. Dectin-2 is best known for its role in pathogen recognition and for stimulating immune responses against foreign pathogens. But here we’re actually trying to leverage this expression by TAMs to stimulate an immune response against the cancer rather than against some foreign pathogen. And we are targeting these TAMs using…
Tumor-Associated Macrophages: BDC-3042 Animal Model Dr. Kenkel SITC 2022 What are tumor-associated macrophages? Our antibody that we refer to as BDC-3042 targets a molecule known as Dectin-2. This is a potent immune-activating receptor expressed by tumor-associated macrophages, or TAMs, across various types of human solid tumors. Dectin-2 is best known for its role in pathogen recognition and for stimulating immune responses against foreign pathogens. But here we’re actually trying to leverage this expression by TAMs to stimulate an immune response against the cancer rather than against some foreign pathogen. And we are targeting these TAMs using our antibody, which specifically…
Omentum Based Reconstruction: For Pts with BMI < 25 kg/m Dr. Wapnir SABCS 2022 Will this data analysis or data collection help with patients that receive omentum based reconstruction? One of the benefits that we’re noticing about this procedure is that patients really do not suffer any of the classical morbidities associated with donor sites. Prolonged drainage, large scars, and other deformities seem to have shortened the length of stay in the hospital, and again, there have been no donor sites or symptoms of donor site morbidities for many years. Dr. Nguyen and I recognized that there was an…
iFrame is not supported! How will the decreases in circulating tumor associated cells help patients with metastatic breast cancer? The Other clinical trial looked at circulating tumor associated cells to look at progression-free survival, overall survival. In our pooled analysis of all of our Bria-IMT trials to date where we had done these analyses, we’ve been collaborating with Creative Microtech, Dan Adams is the first author on this poster, and they have developed a very interesting biomark called Cancer Associated Macrophage Like Cells, abbreviated CAMLs, and I’m sure many of you are familiar with circulating tumor cells as a biomarker…
SV-BR-1-GM: Pooled Analysis Predicts PFS and OS Dr. Williams SABCS 2022 How will the decreases in circulating tumor associated cells help patients with metastatic breast cancer? The Other clinical trial looked at circulating tumor associated cells to look at progression-free survival, overall survival. In our pooled analysis of all of our Bria-IMT trials to date where we had done these analyses, we’ve been collaborating with Creative Microtech, Dan Adams is the first author on this poster, and they have developed a very interesting biomark called Cancer Associated Macrophage Like Cells, abbreviated CAMLs, and I’m sure many of you are…
iFrame is not supported! Car- T DDBMCA By Matthew Frigault, MD Car T cell DDBMCA is a autologous chimeric enogen receptor T-cell. So it’s a type of an immunogen therapy that targets BCMA, which is antigen on multiple myeloma. It is a first.Study until this hasn’t been used in other patients for other reasons or other indications. There are other BCMA car T-cell therapy but this is built differently to hopefully be more effective. And it is a phase 1 dose escalation first in human study.So this was we looked at patients who were defined as relapse refractory. So it…
iFrame is not supported! Axi-cel: Zuma 7 was a randomized phase three study By Armin Ghobadi, MD Zuma 7 was a randomized phase three study that used Axi-Cel versus a standard of. Care chemotherapy followed by autologous transplant.In a second line setting for most patients with relapsed refractory large B-cell lymphoma. That means adult patient with relapse refractory large B-cell lymphoma being refractory to the first line therapy or relapse within the first 12 months of therapy, they’re randomized to access lc, the 19 car versus the standard of care that was chemo followed by. Axi-Cel outcome was superior to…